Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncology Based In-Vivo CRO Market Grown from 2024 to 2025?

The market size of in-vivo CRO that is focused on oncology has experienced substantial growth in the past years. It is projected to escalate from $1.39 billion in 2024 to about $1.5 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.0%. This growth over the historical period is linked with an escalating focus on cancer therapeutics, a surge in cancer occurrences, a shift towards individualized medicine, expansion in the pharmaceutical sector, and the increasing need for therapies aimed at specific targets.

What Growth Rate Is Anticipated for the Oncology Based In-Vivo CRO Market in the Coming Years?

The size of the in-vivo contract research organization (CRO) market focused on oncology is anticipated to witness a quick expansion in the years to come. It is projected to increase to “$2.28 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. This escalation during the forecast period can be ascribed to factors like the surfacing of fresh market prospects, a transition towards immuno-oncology treatment modalities, an increment in oncology clinical trials, the advent of precision medicine, and targeted therapies. Dominant trends expected during this period include the incorporation of regenerative medicine and cell therapies, an increased demand for expedited drug development, the embrace of digitalization and data analytics, a focus on the tumor microenvironment, and a surge in biologics and immunotherapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Who Are the Leading Companies in the Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

What Are the Key Drivers of the Oncology Based In-Vivo CRO Market?

The escalating prevalence of cancer is projected to catalyze the amplification of the oncology-focused in-vivo CRO market’s progress. Cancer, an umbrella term for a collection of diseases where abnormal cells multiply and spread without control, crosses normal barriers, originates almost anywhere within the body’s organs or tissues, and disseminates through blood and lymph systems to other sections of the body. The process of cancer treatment and identification necessitates innovative medications and technologies that must pass through various preclinical studies, clinical tests, and regulatory procedures before introduction to the market. An oncology-focused in-vivo CRO, a firm contracted by a sponsor company, offers services like executing complete or partial stages of running an in-vivo preclinical study. This involves testing on living entities, such as animals, plants, or cells, prior to the trial of the drug or device on humans. The increasing cancer rates have led to a surge in demand for innovative treatments, thus propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, The American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related fatalities and around 1.9 million fresh cancer cases diagnosed within the country in 2022. Predictions suggest nearly 620,000 cancer deaths, marking a mild escalation in mortality rates for 2024. Therefore, the escalating prevalence of cancer is fueling the development of the oncology-based in-vitro CRO market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

What Are the Key Market Segments in the Oncology Based In-Vivo CRO Industry?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Hospitals, Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

What Are the Latest Trends in the Oncology Based In-Vivo CRO Market?

Leading organizations in the oncology-focused in vivo CRO market are honing in on personalized cancer models to secure a competitive edge. These tailor-made oncology models employ patient-derived xenografts (PDXs) to devise treatment plans that fortify the significance and effectiveness of preclinical investigations. For example, Charles River Laboratories, an American life sciences firm, rolled out its OncoMouse platform in 2022, harnessing the power of PDX technology for more precise tumor simulation. This platform is equipped with high-capacity screening capabilities and live tracking of tumor development, facilitating swift evaluation of treatment outcomes. Moreover, it offers comprehensive data analytics to refine treatment methods, taking into account individual patient data. These progressive steps mark a transformation towards more efficient, patient-focused methods in cancer study.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are the Key Regional Markets in the Oncology Based In-Vivo CRO Industry?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

This Report Delivers Insight On:

1. How big is the oncology based in-vivo cro market, and how is it changing globally?

2. Who are the major companies in the oncology based in-vivo cro market, and how are they performing?

3. What are the key opportunities and risks in the oncology based in-vivo cro market right now?

4. Which products or customer segments are growing the most in the oncology based in-vivo cro market?

5. What factors are helping or slowing down the growth of the oncology based in-vivo cro market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model